gefitinib has been researched along with Genetic Predisposition in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gotoda, H; Hotta, K; Ichihara, E; Ichimura, K; Kato, Y; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Ninomiya, K; Ohashi, K; Tamura, T; Tanaka, T | 1 |
| Hagiwara, K; Kondoh, Y; Lasky, JA; Saito, S | 1 |
| Burki, TK | 1 |
| Bontognali, S; Brutsche, MH; Buess, M; Fischer, C; Pless, M; Rochlitz, C | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Ito, K; Kinoshita, I; Kobayashi, K; Kurihara, M; Maemondo, M; Minato, K; Morita, S; Nishitsuji, M; Nukiwa, T; Oizumi, S; Sugawara, S; Yoshizawa, H | 1 |
| Ahn, MJ; Atagi, S; Jiang, H; Kim, SW; Lee, DH; Liu, Y; Lu, Y; Mok, TS; Nakagawa, K; Ponce, S; Shi, X; Soria, JC; Wang, J; Webster, A; Wu, YL; Yang, JC; Yang, JJ; Yoh, K; Zhou, JY | 1 |
| Fu, F; Geng, J; Sun, D; Wang, H; Xie, X; Yu, G; Zhang, L | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, TM; Kim, YW; Lee, SH; Park, S; Suh, B | 1 |
| Dietel, M; Eberhardt, W; Griesinger, F; Radke, S; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
| Aleksakhina, SN; Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Kozyreva, KS; Kramchaninov, MM; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Preobrazhenskaya, EV; Shelekhova, KV; Venina, AR; Volkov, NM; Zhuravlev, AS | 1 |
| Chai, Y; Yu, T; Zhu, Z | 1 |
| Azuma, A; Hagiwara, K; Kudoh, S | 1 |
| Goto, Y; Hojo, M; Kobayashi, N; Kudo, K; Takeda, Y | 1 |
| Boggon, TJ; Cappuzzo, F; Clifford, B; Eisenberg, R; Franklin, WA; Fu, P; Halmos, B; Hamdan, A; Hirsch, FR; Jin, C; Leidner, RS; Skokan, M; Varella-Garcia, M | 1 |
| Wörmann, B | 1 |
| Chung, KP; Shih, JY; Yu, CJ | 1 |
| Ando, M; Hasegawa, Y; Horio, M; Horio, Y; Kondo, M; Saito, H; Tamura, M; Yamamoto, M | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A | 1 |
| Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C | 1 |
| Kudo, S | 1 |
| Eguchi, K; Hisamoto, A; Kiura, K; Kozuki, T; Mandai, K; Nakata, M; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Guo, AL; Wang, Z; Wu, YL; Xu, CR; Zhang, GC; Zhou, Q | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
4 review(s) available for gefitinib and Genetic Predisposition
| Article | Year |
|---|---|
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective.
Topics: Asian People; Cause of Death; Disease Progression; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Japan; Lung Neoplasms; Male; Pneumonectomy; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Survival Rate | 2018 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
[Drug induced lung injuries in Japanese population].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Asian People; Bleomycin; Gefitinib; Genetic Predisposition to Disease; Humans; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial; Pulmonary Alveoli; Quinazolines; Racial Groups | 2006 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
5 trial(s) available for gefitinib and Genetic Predisposition
| Article | Year |
|---|---|
Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2013 |
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Europe; Female; Gefitinib; Genetic Predisposition to Disease; Glutamates; Guanine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenomic Testing; Point Mutation; Prevalence; Quinazolines; Radiation Injuries; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prevalence; Quinazolines; Risk Factors; Russia; Treatment Outcome | 2016 |
16 other study(ies) available for gefitinib and Genetic Predisposition
| Article | Year |
|---|---|
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Interleukin-6; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Prevalence; Quinazolines; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
Preliminary activity of capmatinib with gefitinib in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Genetic Predisposition to Disease; Humans; Imidazoles; Lung Neoplasms; Maximum Tolerated Dose; Mutation; Phenotype; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; Triazines | 2018 |
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; China; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Nutrition Assessment; Nutritional Status; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Multiple primary lung cancer displaying different EGFR and PTEN molecular profiles.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Phenotype; Pneumonectomy; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients.
Topics: Acute Disease; Asian People; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2008 |
Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Lung Neoplasms; Methylprednisolone; Muscular Diseases; Prednisolone; Quinazolines | 2010 |
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Quinazolines; ras Proteins; Risk Assessment; White People | 2009 |
Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chemotherapy, Adjuvant; Cholecystitis; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Incidental Findings; Lung Neoplasms; Mutation; Neoplasm Staging; Pedigree; Pneumonectomy; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vinorelbine | 2010 |
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Gefitinib; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Phenotype; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Quinazolines; Real-Time Polymerase Chain Reaction | 2012 |
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin | 2004 |
Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines; Tobacco Smoke Pollution | 2007 |
Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenomatosis, Pulmonary; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Quinazolines; Retrospective Studies | 2007 |
EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2008 |